Loading...
•
Sep 30, 2021
Surmodics Q4 2021 Earnings Report
Surmodics reported a 6% increase in revenue year-over-year, with a GAAP EPS of $(0.02) and a non-GAAP EPS of $(0.10).
Key Takeaways
Surmodics, Inc. reported its fourth quarter fiscal 2021 results, with revenue increasing by 6% year-over-year. The company's GAAP EPS was $(0.02), and non-GAAP EPS was $(0.10). The company also issued fiscal 2022 revenue and EPS guidance.
Revenue of $24.0 million, an increase of 6% year-over-year
GAAP EPS of $(0.02)
Non-GAAP EPS of $(0.10)
Successful first patient use Sublime™ .018 RX PTA Dilatation Catheter
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million. The Company expects fiscal 2022 diluted GAAP EPS to range from a loss per share of $(2.05) to $(1.55), which reflects increased investments to accelerate the Company’s strategy. Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.75) to $(1.25).
Revenue & Expenses
Visualization of income flow from segment revenue to net income